Drugs / dendritic cell-MART-1 peptide vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00003665 | Apr 1999 → Oct 2002 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005617 | Jul 1997 → Jun 2002 | melanoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00039325 | Mar 2002 → Sep 2005 | cutaneous melanoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dendritic cell-MART-1 peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005617 ↗ |
| Modality | Vaccine | “peptide pulsed DC vaccine” NCT00003665 ↗ |
| Route | Intravenous | “Patients receive 3 different doses of peptide pulsed DC vaccine IV” NCT00003665 ↗ |